BEFORE THE CLAIM: KNOWING YOUR STATE’S WRONGFUL DEATH LAW
When a person is injured by the negligence of another, the question of who will bring the claim is usually straightforward: the injured person. But in wrongful death suits, one of the preliminary...
View ArticlePicking Your Team: Getting the Right Trustee or Personal Representative...
Under federal and state law, an individual retirement account, or IRA, ordinarily may be exempted or excluded from the assets of a bankruptcy estate and, thus, protected from the claims of creditors....
View ArticleEstate Planning for Settlements or Favorable Verdicts
Proper settlement planning can be an invaluable service to a client as a lawsuit approaches an end. Funds from a settlement or favorable verdict may greatly affect the status of your client’s assets...
View ArticleAmarin Pharma, Inc. v. Hikma Pharms USA Inc.
Case Name: Amarin Pharma, Inc. v. Hikma Pharms USA Inc., No. 16-cv-02525, 2020 WL 1517568 (D. Nev. March 30, 2020) (Du, J.) Drug Product and Patent(s)-in-Suit: Vascepa® (icosapent ethyl); U.S. Patents...
View ArticleBelcher Pharms., LLC v. Hospira, Inc.
Case Name: Belcher Pharms., LLC v. Hospira, Inc., No. 17-775-LPS, 2020 WL 1650535 (D. Del. Mar. 31, 2020) (Stark, J.)Drug Product and Patent(s)-in-Suit: epinephrine injection; U.S. Patent No. 9,283,197...
View ArticleNew ANDA Cases
table.tableizer-table { border: 1px solid #666; font-size: 12px; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #666; } .tableizer-table th { background-color: #CCC; color: #FFF;...
View ArticleGeneric Launches
table.tableizer-table { border: 1px solid #666; font-size: 12px; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #666; } .tableizer-table th { background-color: #CCC; color: #FFF;...
View ArticleANDA Litigation Settlements
table.tableizer-table { border: 1px solid #666; font-size: 12px; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #666; } .tableizer-table th { background-color: #CCC; color: #FFF;...
View ArticleANDA Approvals
table.tableizer-table { border: 1px solid #666; font-size: 12px; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #666; } .tableizer-table th { background-color: #CCC; color: #FFF;...
View ArticleThree Myths the Pandemic Has Debunked: What They Can Teach Law Firms about...
With apologies to Jane Austen, it is a truth universally acknowledged that the legal field is in want of diversity. Change is glacial in the practice of law, a risk-averse sector where seniority and...
View ArticleMentoring Diverse Attorneys During the Pandemic
The value of mentoring in the legal profession cannot be overstated. From a diversity and inclusion perspective, it is critical. But with remote working, diverse attorneys face new challenges that may...
View ArticleInterview with Lauren Bernstein, Director at Curiam Capital LLC
One of the more noteworthy developments over the past few years in the litigation arena has been the rise of litigation funding. A newer name in the industry is Curiam Capital LLC, launched in 2018 by...
View ArticleThe Cure: Social Media Influencers and Healthcare
Social media influencers have become the latest source of health information for many. This is especially true right now, amidst the ongoing and rapidly evolving COVID-19 pandemic. More and more...
View ArticleInterview with Stacey Slaughter, Partner at Robins Kaplan LLP
One of our attorneys sits down with Stacey Slaughter, a partner at Robins Kaplan. Ms. Slaughter shares with us insight into her career as a class action litigator and the noteworthy case against Fiat...
View ArticleWhat's a Fiduciary To Do? Considerations for Periods of Uncertainty
In the face of complex disruptions of the sort we have recently experienced, new challenges emerge and old challenges are exacerbated. For those who have undertaken fiduciary obligations to others,...
View ArticleWhat Could be the Harm? Minnesota's Harmless Error Statute
Against the backdrop of a global pandemic, many clients developed a newfound sense of urgency regarding their estate planning, which presented new challenges in light of the attendant health risks and...
View ArticleThe Brave New World of Virtual Notarization
The COVID-19 pandemic and consequent state and federal guidelines forced people to work from home before they were able to take steps so that they could do so effectively. This new working dynamic...
View ArticleCelgene Corp. v. Sun Pharma Global FZE
Case Name: Celgene Corp. v. Sun Pharma Global FZE, No. 19-10099 (SDW) (LDW), 2020 WL 1921700 (D.N.J. Apr. 6, 2020) (Wigenton, J.) Drug Product and Patent(s)-in-Suit: Revlimid® (lenalidomide); U.S....
View ArticleValeant Pharms Int’l, Inc. v. Mylan Pharms Inc.
Case Name: Valeant Pharms Int’l, Inc. v. Mylan Pharms Inc., No. 2018-2097, 2020 WL 1698591 (Fed. Cir. April 8, 2020) (Circuit Judges Lourie, Reyna, and Hughes presiding; Opinion by Lourie, J.) (Appeal...
View ArticleSomaxon Pharma, Inc. v. Actavis Elizabeth LLC
Case Name: Somaxon Pharma, Inc. v. Actavis Elizabeth LLC, No. 10-1100, 2020 WL 1903171 (D. Del. April 9, 2020) (Fallon, J.)Drug Product and Patent(s)-in-Suit: Silenor® (doxepin hydrochloride); U.S....
View ArticleBiogen Int'l GmbH v. Banner Life Scis. LLC
Case Name: Biogen Int'l GmbH v. Banner Life Scis. LLC, 956 F.3d 1351 (Fed. Cir. April 21, 2020)(Circuit Judges Lourie, Moore, and Chen presiding; Opinion by Lourie, J.) (Appeal from D. Del., Stark, J.)...
View ArticleCephalon, Inc. v. Slayback Pharma Ltd.
Case Name: Cephalon, Inc. v. Slayback Pharma Ltd., No. 17-1154-CFC, 2020 WL 1983730 (D. Del. April 27, 2020) (Connolly, J.) Drug Product and Patent(s)-in-Suit: Bendeka® (bendamustine hydrochloride);...
View ArticleOnyx Therapeutics, Inc. v. Cipla Ltd.
Case Name: Onyx Therapeutics, Inc. v. Cipla Ltd., No. 16-988-LPS, 2020 WL 2214443 (D. Del. May 4, 2020) (Stark, J.) Drug Product and Patent(s)-in-Suit: Kyprolis® (carfilzomib); U.S. Patents Nos....
View ArticleEagle Pharms. Inc. v. Slayback Pharma LLC
Case Name: Eagle Pharms. Inc. v. Slayback Pharma LLC, 958 F.3d 1171 (Fed. Cir. May 8, 2020) (Circuit Judges O’Malley, Reyna, and Chen presiding; Opinion by Reyna, J.) (Appeal from D. Del., Connolly,...
View ArticleBiogen Int’l GmbH v. Mylan Pharms. Inc.
Case Name: Biogen Int’l GmbH v. Mylan Pharms. Inc., No. 1:17-cv-116, 2020 WL 3317105 (N.D.W.V. June 18, 2020) (Keeley, J.) Drug Product and Patent(s)-in-Suit: Tecfidera® (dimethyl fumarate); U.S....
View ArticleFerring Pharms. Inc. v. Lupin Inc.
Case Name: Ferring Pharms. Inc. v. Lupin Inc., No. 19-913-RGA, 2020 WL 3414750 (D. Del. June 22, 2020) (Andrews, J.) Drug Product and Patent(s)-in-Suit: Clenpiq® (sodium picosulfate / magnesium oxide /...
View ArticleAdapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc.
Case Name: Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc., No. No. 16-7721 (BRM) (JAD), 2020 WL 3428078 (D.N.J. June 22, 2020) (Martinotti, J.) Drug Product and Patent(s)-in-Suit: Narcan®...
View ArticleH. Lundbeck A/S v. Apotex Inc.
Case Name: H. Lundbeck A/S v. Apotex Inc., No. 18-88-LPS, 2020 WL 3507795 (D. Del. June 26, 2020) (Stark, J.) Drug Product and Patent(s)-in-Suit: Trintellix® (vortioxetine); U.S. Patents Nos. 8,722,684...
View ArticleNew ANDA Cases
This chart summarizes the case name, presiding judge, drug, and patents-at-issue in all federal district court cases that are filed pursuant to the Hatch-Waxman Act. It also includes the same...
View ArticleGeneric Launches 505(b)(2)
This chart tracks the date, drug, reference-listed company, applicant, and indications of publicly available drug launches resulting from Abbreviated New Drug Applications and 505(b)(2) Applications....
View ArticleANDA Litigation Settlements
This chart summarizes the case name, drug, patents-in-suit, and publicly available terms for reported settlements in federal district court cases that are filed pursuant to the Hatch-Waxman Act....
View ArticleANDA Approvals
This chart tracks the date, drug, reference-listed company, and applicant of Abbreviated New Drug Applications and 505(b)(2) Applications receiving final approval by the FDA. table.tableizer-table {...
View ArticleFacing Novel Legal Issues Concerning Facial Recognition Technology in 2020
“Beware the Kodak,” warned TheHartfordDaily Courant in July 1888. “The sedate citizen can’t indulge in any hilariousness without incurring the risk of being caught in the act and having his photograph...
View ArticleInterview with Uzma Saghir, Senior Corporate Counsel at Liberty Mutual
Tell me about your current role.I work on the corporate side, for two main clients – Procurement and Meeting Management and Event Strategy. For Procurement, Liberty spends over $12 billion a year with...
View ArticleDon’t Stop the Music: The Intersection Between Insurance and The Music...
Several industries have been severely hit by the COVID-19 pandemic, and the music industry is certainly no exception. Although many artists have found creative ways to monetize their craft, such as...
View ArticleConservation Easement Deductions: How Recent Tax Law Developments Have...
I. Introduction A recent development in tax law has created a new, fertile area for recovery of losses via legal malpractice litigation. For years, tax attorneys recommended conservation easements to...
View ArticleTakeda Pharms. U.S.A., Inc. v. Mylan Pharms. Inc.
Case Name: Takeda Pharms. U.S.A., Inc. v. Mylan Pharms. Inc., No. 2020-1407, -1417 (Fed. Cir. July 31, 2020) (Circuit Judges Prost, Newman, and Hughes presiding; Opinion by Prost, C.J.; Dissent by...
View ArticleIBSA Institut Biochimique, S.A. v. Teva Pharms. USA, Inc.
Case Name: IBSA Institut Biochimique, S.A. v. Teva Pharms. USA, Inc., No. 2019-2400 (Fed. Cir. July 31, 2020) (Circuit Judges Prost, Reyna, and Hughes presiding; Opinion by Prost, C.J.) (Appeal from D....
View ArticleBristol-Myers Squibb Co. v. Aurobindo Pharma USA Inc.
Case Name: Bristol-Myers Squibb Co. v. Aurobindo Pharma USA Inc., No. 17-374-LPS (Consolidated), 2020 WL 4500226 (D. Del. Aug. 5, 2020) (Stark, J.) Drug Product and Patent(s)-in-Suit: Eliquis®...
View ArticleSun Pharm. Indus. Ltd. v. Saptalis Pharms., LLC
Case Name: Sun Pharm. Indus. Ltd. v. Saptalis Pharms., LLC, No. 18-648-WCB, 2020 WL 5077412 (D. Del. Aug. 6, 2020) (Bryson, J.) Drug Product and Patent(s)-in-Suit: Riomet® (metformin HCl); U.S. Patent...
View ArticleNovartis Pharms. Corp. v. Accord Healthcare Inc.
Case Name: Novartis Pharms. Corp. v. Accord Healthcare Inc., No. 18-1043-KAJ (D. Del. August 10, 2020) (Jordan, J.) Drug Product and Patent(s)-in-Suit: Gilenya® (fingolimod); U.S. Patent No. 9,187,405...
View ArticleNoven Pharm., Inc. v. Amneal Pharms. LLC
Case Name: Noven Pharm., Inc. v. Amneal Pharms. LLC, No. 18-cv-00699 (D. Del. Sept. 2, 2020) (Stark, J.) Drug Product and Patent(s)-in-Suit: Minivelle® (estradiol); U.S. Patents Nos. 9,833,419 (“the...
View ArticleBiogen Int’l GmbH v. Amneal Pharmaceuticals LLC
Case Name: Biogen Int’l GmbH v. Amneal Pharmaceuticals LLC, Civ. No. 17-823 (MN), 2020 WL 5549084 (D. Del. Sept. 16, 2020) (Noreika, J.) Drug Product and Patent(s)-in-Suit: Tecfidera® (dimethyl...
View ArticleNew ANDA Cases
This chart summarizes the case name, presiding judge, drug, and patents-at-issue in all federal district court cases that are filed pursuant to the Hatch-Waxman Act. It also includes the same...
View ArticleGeneric Launches
This chart tracks the date, drug, reference-listed company, applicant, and indications of publicly available drug launches resulting from Abbreviated New Drug Applications and 505(b)(2) Applications....
View ArticleANDA Litigation Settlements
This chart summarizes the case name, drug, patents-in-suit, and publicly available terms for reported settlements in federal district court cases that are filed pursuant to the Hatch-Waxman Act....
View ArticleANDA Approvals
This chart tracks the date, drug, reference-listed company, and applicant of Abbreviated New Drug Applications and 505(b)(2) Applications receiving final approval by the FDA. table.tableizer-table {...
View ArticleValuation: The “Eye of the Beholder” Causes Disputes
The need to value closely held corporations and associated real estate frequently arises in the context of estate administration. The value of such assets, however, is often fogged by the differing...
View ArticleThe IRS Says “Nice Try.” Case Illustrations of Unsuccessful Valuation Efforts
In the context of valuation, legal professionals have at times utilized creative efforts to shield clients from tax exposure. It is perhaps unsurprising therefore that whether the focus involves art, a...
View ArticleFrom the Trenches: A Spotlight Interview with Larry Farese
The Spotlight had a chance to sit down with longtime Robins Kaplan trial attorney and mediator Larry Farese for a good old-fashioned story telling session.
View Article